Induction of T-helper-17-cell-mediated anti-tumour immunity by pathogen-mimicking polymer nanoparticles.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36564626.
- Also identified by DOI 10.1038/s41551-022-00973-4 and PMC identifier 9877201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effectivity of cancer immunotherapies is hindered by immunosuppressive tumour microenvironments that are poorly infiltrated by effector T cells and natural killer cells. In infection and autoimmune disease, the recruitment and activation of effector immune cells is coordinated by pro-inflammatory T helper 17 (T<sub>H</sub>17) cells. Here we show that pathogen-mimicking hollow nanoparticles displaying mannan (a polysaccharide that activates T<sub>H</sub>17 cells in microbial cell walls) limit the fraction of regulatory T cells and induce T<sub>H</sub>17-cell-mediated anti-tumour responses. The nanoparticles activate the pattern-recognition receptor Dectin-2 and Toll-like receptor 4 in dendritic cells, and promote the differentiation of CD4<sup>+</sup> T cells into the T<sub>H</sub>17 phenotype. In mice, intra-tumoural administration of the nanoparticles decreased the fraction of regulatory T cells in the tumour while markedly increasing the fractions of T<sub>H</sub>17 cells (and the levels of T<sub>H</sub>17-cell-associated cytokines), CD8<sup>+</sup> T cells, natural killer cells and M1-like macrophages. The anti-tumoural activity of the effector cells was amplified by an agonistic antibody against the co-stimulatory receptor OX40 in multiple mouse models. Nanomaterials that induce T<sub>H</sub>17-cell-mediated immune responses may have therapeutic potential.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Nanoparticles